TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18355507
Drug: Intravenous cariporide
Normalized name: Cariporide
DrugBank: Cariporide (DB06468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cariporide (180 mg in a 1-hour preoperative loading dose, then 40 mg per hour over 24 hours and 20 mg per hour over the subsequent 24 hours)
Study: 18355507
Drug: Intravenous cariporide
Normalized name: Cariporide
DrugBank: Cariporide (DB06468)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cariporide
Study: 12609781
Drug: Lymecycline 300
Normalized name: lymecycline 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymecycline 300 mg od
Study: 12609781
Drug: Lymecycline 150
Normalized name: lymecycline 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymecycline 150 mg bid
Study: 10396008
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (pharmacotherapy + cognitive‐behavioral psychotherapy)
Study: 7555472
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (insulin + OHAs)
Study: 7555472
Drug: Insulin group
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin group (insulin alone)
Study: 2100046
Drug: Apomorphine (different
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (different doses, subcutaneously)
Study: 395630
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g intravenously six times daily for a maximum of 3 days, followed by 1.5 g orally four times daily for a maximum of 4 days)
Study: 25964070
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg and 8 mg daily
Study: 19166691
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/day (monotherapy)
Study: 19166691
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/day (add-on to statin therapy)
Study: 29634656
Drug: Prolastin C,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolastin C, plasma-derived AAT, at 60 mg/kg infused intravenously within 12 hours of reperfusion
Study: 27513506
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (2.24 g daily) in skim milk (350 ml twice daily) for 3 weeks
Study: 16554145
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg the day before and 1200 mg on race day)
Study: 12610048
Drug: Participants on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants on hypoglycemic agents
Study: 10771455
Drug: Ziprasidone 40
Normalized name: ziprasidone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 40 mg + Cimetidine 800 mg
Study: 10771455
Drug: Ziprasidone 40
Normalized name: ziprasidone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 40 mg + Maalox
Study: 10771455
Drug: Ziprasidone 40
Normalized name: ziprasidone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 40 mg alone
Study: 9238880
Drug: Oral‐B 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B 35 manual toothbrush (Control)
Study: 1450081
Drug: Standard protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protocol treatment
Study: 7442597
Drug: Etofibrate (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etofibrate (500 mg, sustained release, 1 capsule per day)
Study: 26987409
Drug: Glucose solutions
Normalized name: glucose Injectable Solution
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose solutions (4%, 16%, 48%)
Study: 22198979
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy for 3 nights starting the first night after stroke onset, with additional nights based on apnea-hypopnea index results.
Study: 22198979
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy (excellent use)
Study: 22198979
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy (some use)
Study: 10580624
Drug: Nasal mupirocin
Normalized name: mupirocin Nasal Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal mupirocin calcium ointment 2% administered twice a day for 5 days followed by twice monthly applications.
Study: 10580624
Drug: Nasal mupirocin
Normalized name: mupirocin Nasal Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal mupirocin calcium ointment 2%
Study: 6223584
Drug: SPG (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPG (20 mg twice a week or 40 mg once a week) with MF protocol (mitomycin C + 5-fluorouracil)
Study: 6223584
Drug: SPG (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPG (20 mg twice a week or 40 mg once a week) with F protocol (tegafur)
Study: 30826311
Drug: Tolnaftate solution
Normalized name: Tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolnaftate solution
Study: 27641510
Drug: Rabeprazole (PPI),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (PPI), 20 mg once daily
Study: 27641510
Drug: Famotidine (H2RA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (H2RA), 40 mg once daily
Study: 19761718
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg film‐coated tablet of avosentan
Study: 19761718
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg film‐coated tablet of avosentan
Study: 19761718
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg avosentan in 20 ml solution for infusion
Study: 15319761
Drug: Chiropractic adjustments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic adjustments with placebo medicine
Study: 15319761
Drug: Placebo medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medicine with sham adjustments
Study: 11003931
Drug: Hemodynamic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodynamic treatment guided by gastric intramucosal pH monitoring
Study: 1389938
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of the 5 mu diameter particle
Study: 1389938
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of the 2 mu diameter particle
Study: 6208841
Drug: Flecainide (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (375 mg)
Study: 6208841
Drug: Quinidine (660
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (660 mg)
Study: 30169436
Drug: Methylphenidate (optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (optimal dose of 40.5 mg, 1.00 mg/kg/day)
Study: 20400412
Drug: Memantine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (40 mg/day or maximum tolerated dose)
Study: 17299464
Drug: Purple sweet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purple sweet potato (PSP) beverage (200.3 mg anthocyanins per 125 ml per bottle), consumed two bottles per day for 8 weeks
Study: 17299464
Drug: Placebo beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beverage (1.7 mg anthocyanins per 125 ml per bottle), consumed two bottles per day for 8 weeks
Study: 15968232
Drug: Metoclopramide (started
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (started at 5 mg daily, titrated to a maximum of 40 mg daily)
Study: 10566623
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of radioiodine WBS and serum Tg after recombinant human TSH stimulation
Study: 1905602
Drug: Bayesian pharmacokinetic
Normalized name: Babesia microti preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bayesian pharmacokinetic dosing program
Study: 1905602
Drug: Dosing based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing based on physician choice (Control)
Study: 6333518
Drug: Prophylactic antibacterial
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibacterial preparation
Study: 6333518
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic antibacterial preparation (Control)
Study: 3578852
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 0.25% bupivacaine
Study: 24627416
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) adherence in E‐ZES group
Study: 11605086
Drug: Gaboxadol 20
Normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaboxadol 20 mg
Study: 11303489
Drug: 4.4 mg
Normalized name: pectin 4.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.4 mg beta-carotene from DGLV (n=37, after 18 dropouts)
Study: 11303489
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg beta-carotene from sweet pumpkin (n=36, 18 dropouts)
Study: 11303489
Drug: DGLV (4.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DGLV (4.4 mg beta-carotene)
Study: 8257551
Drug: Buprenorphine (0.6‐1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.6‐1.2 mg per day, sublingually)
Study: 8257551
Drug: Clonidine (0.3‐0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.3‐0.9 mg per day, oral)
Study: 3084315
Drug: Glibenclamide (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (7 mg before breakfast and 3.5 mg before supper)
Study: 11688590
Drug: Functional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional physical therapy
Study: 11688590
Drug: Reference group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference group physical therapy (normalization of quality of movement)
Study: 27401338
Drug: Glutamine-enriched nutritional
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-enriched nutritional therapy (peptamen + glutamine)
Study: 19785609
Drug: Terbinafine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine with iontophoretic patch (100 microA cm(‐2))
Study: 15607126
Drug: Oral NAC
Normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral NAC 600 mg b.i.d. for 2 months
Study: 12404705
Drug: Ginkgo-Ginseng combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo-Ginseng combination (320 mg)
Study: 12404705
Drug: Ginkgo-Ginseng combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo-Ginseng combination (640 mg)
Study: 12404705
Drug: Ginkgo-Ginseng combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo-Ginseng combination (960 mg)
Study: 10102436
Drug: Albendazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (15 mg/kg/d for 1 week)
Study: 10102436
Drug: Praziquantel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (100 mg/kg in three divided doses at 2‐hour intervals)
Study: 7598284
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg bolus followed by 20-min infusion at 9 micrograms.kg-1.min-1)
Study: 2219614
Drug: Mesterolone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesterolone (20 mg daily for 14 days)
Study: 24894850
Drug: Observation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation with early salvage radiotherapy (SRT) triggered by PSA level >0.20 ng/mL
Study: 20645280
Drug: Treatment satisfaction
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment satisfaction data from four treatment arms
Study: 16260426
Drug: Monascus purpureus
Normalized name: Monascus purpureus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monascus purpureus Went rice (600 mg)
Study: 11185676
Drug: Azithromycin 1200
Normalized name: azithromycin 1200 MG per 30 ML Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1200 mg oral dose
Study: 11185676
Drug: Nelfinavir 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir 750 mg q8h for 11 days with concurrent azithromycin 1200 mg on Day 9
Study: 1825266
Drug: Fenoterol, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol, 100 micrograms/dose
Study: 1825266
Drug: Fenoterol, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol, 200 micrograms/dose
Study: 1825266
Drug: Fenoterol, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol, 50 micrograms and ipratropium, 20 micrograms/dose in a single inhaler (Berodual)
Study: 1825266
Drug: Fenoterol, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol, 100 micrograms and ipratropium, 40 micrograms/dose in a single inhaler (Duovent)
Study: 1825266
Drug: High-dose combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose combination
Study: 1825266
Drug: Low-dose fenoterol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fenoterol and low-dose combination
Study: 29552984
Drug: Edoxaban plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban plus aspirin
Study: 27846071
Drug: Detectable breastmilk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detectable breastmilk RNA (≥40 copies/mL)
Study: 22782052
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide (Ca(OH)2) and 2% chlorhexidine gel (CHX)
Study: 19475583
Drug: Antipsychotic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medications (specific medications not detailed)
Study: 12163424
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus moderate-intensity coumarin (3-month regimen)
Study: 3046350
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir (5 mg/kg every eight hours) for five days
Study: 17327249
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (including pelvic floor muscle training and exercise and bladder control strategies)
Study: 17327249
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intravaginal continence pessary and behavioral therapy
Study: 11943517
Drug: Transdermal nitroglycerine
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerine 5-mg/24-hour patch
Study: 1100299
Drug: Sodium secobarbital
Normalized name: Secobarbital Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium secobarbital (150 mg/70 kg)
Study: 1100299
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of marihuana and secobarbital
Study: 6102180
Drug: Cefazolin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (3 doses of 1 g each)
Study: 21175792
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with probiotic-containing yogurt (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium longum, and Streptococcus thermophilus)
Study: 21175792
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy without yogurt (control group)
Study: 21175792
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with probiotic-containing yogurt
Study: 17361128
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg loading dose, 15 mg maintenance dose) with ketoconazole (400 mg/day)
Study: 17361128
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose, 75 mg maintenance dose) with ketoconazole (400 mg/day)
Study: 17361128
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg loading dose, 75 mg maintenance dose) without ketoconazole
Study: 17361128
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg loading dose, 15 mg maintenance dose) without ketoconazole
Study: 8144266
Drug: 0.85 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.85 g/kg dose of alcohol
Study: 26418666
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + L (scaling and root planing plus adjunctive laser therapy)
Study: 26418666
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + L
Study: 23223117
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg IV ketamine (group K)
Study: 21669126
Drug: Intramuscular interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular interferon β‐1a (IM IFN‐β‐1a)
Study: 19136898
Drug: Rapid discontinuation
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid discontinuation of prednisone (RDP)
Study: 16962524
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg granisetron (Group A, n=70)
Study: 16962524
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (Group B, n=70)
Study: 8766398
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (PCA) with piritramide (bolus 2.5 mg, blocking time 20 minutes, no basal infusion)
Study: 8766398
Drug: Epidural anaesthesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural anaesthesia with bupivacaine 0.5% and intravenous PCA (same parameters as group 1) plus continuous epidural infusion of bupivacaine 0.1875% at 8 ml/h
Study: 7201271
Drug: Fentanyl, 8
Normalized name: FentaNYL, 800 mcg buccal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl, 8 micrograms/kg with thiopental, 3 mg/kg
Study: 7201271
Drug: Thiopental, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental, 6 mg/kg alone
Study: 29663701
Drug: RAL 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAL 0.1% cream
Study: 29663701
Drug: RAL 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAL 0.05% cream
Study: 26850746
Drug: n-3 PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFAs (∼1.8 g/day) for ∼14 days
Study: 20403018
Drug: Alcoholic beverage
Normalized name: Alcoholic beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcoholic beverage (mean = 0.12 g% breath alcohol concentration)
Study: 18316629
Drug: Hyperinsulinemia (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemia (plasma insulin increased to 400 pmol/L)
Study: 12610003
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg daily (Irb150)
Study: 12610003
Drug: Irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 300 mg daily (Irb300)
Study: 8602660
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg x kg‐1 cisatracurium
Study: 8602660
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg x kg‐1 cisatracurium
Study: 6461281
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (40 mcg from a metered dose inhaler)
Study: 30640362
Drug: Exenatide 2
Normalized name: exenatide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 2 mg once weekly for 48 weeks
Study: 22908773
Drug: Potassium citrate
Normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Potassium citrate and dry extract of Agropyrum repens (CalcoMEV) at the dose of 24 mEq of potassium citrate and 100 mg of dry extract of Agropyrum repens bis in die
Study: 22908773
Drug: Potassium citrate
Normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Potassium citrate at a dose of 20 mEq ter in die
Study: 17661767
Drug: Oral sotalol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sotalol (80 mg twice daily) and magnesium supplementation
Study: 1390141
Drug: 0.05% solution
Normalized name: Equate Nasal Spray 0.05% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% solution of a commercial dish-washing product (three times/day, for 15 min, at 37 degrees C) for 3 weeks
Study: 31647496
Drug: Intravitreous ranibizumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreous ranibizumab, 0.5 mg, at baseline and as frequently as every 4 weeks
Study: 27362442
Drug: ACE (2.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE (2.3 g/day)
Study: 26176940
Drug: Standard EC-MPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard EC-MPS dosing (1440 mg/day) with low exposure to CsA (4.5 mg/kg/day for low risk DGF, 2.5 mg/kg/day for high risk DGF)
Study: 26176940
Drug: Standard EC-MPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard EC-MPS dosing (1440 mg/day) with low exposure to CsA
Study: 23714268
Drug: Azithromycin 250
Normalized name: azithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 250 mg three times per week for 3 months
Study: 21621886
Drug: Low-volume enteral
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume enteral supplement containing key nutrients
Study: 21621886
Drug: Diluted standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted standard nutrition solution
Study: 16824845
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus GPIIb/IIIa inhibitors
Study: 10836008
Drug: High-dose IFN‐α(2b)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFN‐α(2b)
Study: 10836008
Drug: Lymphadenectomy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphadenectomy or adjuvant IFN‐α(2b) therapy
Study: 9643529
Drug: GMDP solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMDP solution (0.5-1.0 mg daily)
Study: 9643529
Drug: GMDP solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMDP solution (1.5 mg/kg daily)